We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01205412
First Posted: September 20, 2010
Last Update Posted: November 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
September 16, 2010
September 20, 2010
November 22, 2012
October 2010
November 2011   (Final data collection date for primary outcome measure)
Prevalence of any Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) and HPV type distribution among women undergoing cervical sample testing and post-natal check up. [ Time Frame: Average time frame: 12 months ]
Prevalence of any Human Papillomavirus (HPV) DNA and HPV type distribution among women undergoing cervical sample testing and post-natal check up. [ Time Frame: Average time frame: 12 months ]
Complete list of historical versions of study NCT01205412 on ClinicalTrials.gov Archive Site
  • Prevalence of any HPV DNA and HPV type distribution among women of different age strata undergoing cervical sample testing and post-natal check up. [ Time Frame: Average time frame: 12 months ]
  • Behavioural risk factors [ Time Frame: During visit 1 (day 0) ]
  • Awareness of HPV in relation to transmission and cause of cervical cancer [ Time Frame: Average time frame: 12 months ]
Same as current
Not Provided
Not Provided
 
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women in the Kingdom of Bahrain
The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for post-natal check up in the Kingdom of Bahrain.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Endocervical samples
Non-Probability Sample
Women ≥ 20 years of age, attending out-patient health services for routine cervical screening and women ≥ 16 years of age presenting for post-natal check up in the Kingdom of Bahrain.
Human Papillomavirus Infection
Procedure: Endocervical samples
Endocervical samples collection during routine gynaecological examinations
Assessed Cohort
Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
Intervention: Procedure: Endocervical samples
Moosa K, Alsayyad AS, Quint W, Gopala K, DeAntonio R. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014 Dec 3;14:905. doi: 10.1186/1471-2407-14-905.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
552
November 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women ≥ 20 years of age attending a clinic for routine cervical screening OR
  • Women ≥ 16 years of age presenting for post-natal check-ups
  • Women providing a cervical sample
  • Written informed consent or oral-witnessed thumb printed informed consent obtained from the subject

Exclusion Criteria:

  • Referral for abnormal cervical sample at the current visit
  • Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (Note: Enrolment can be delayed until this condition is resolved)
  • Pregnant women
  • History of hysterectomy
  • Known diagnosis of immunosuppression, or patient on immunosuppressives
  • Having received one or more doses of human papillomavirus vaccine prior to participating in the study
Sexes Eligible for Study: Female
16 Years and older   (Child, Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Bahrain
 
 
NCT01205412
112710
Not Provided
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
November 2012